Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|November 4, 2000
Progress in active-specific immunotherapy of brain malignanciesB A Tjoa, M L SalgallerJournal of Surgical Oncology|June 12, 1998
Use of cellular and cytokine adjuvants in the immunotherapy of cancerM L Salgaller, P A LodgeThe Journal of General Virology|September 1, 1992
Dissociable antiviral activities directed against cardioviruses are expressed in L cells treated with interferonS J Monahan, E SimonJournal of Immunotherapy (Hagerstown, Md. : 1997)|July 1, 1997
Expression of MAGE genes in ocular melanoma cell linesP W Chen, T G Murray, M L Salgaller, et al.Cancer Research|May 1, 1993
Baculovirus recombinants expressing the human carcinoembryonic antigen geneM L Salgaller, R Bei, J Schlom, et al.International Journal of Cancer|October 21, 1996
MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumorsH Ishida, T Matsumura, M L Salgaller, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cellsF M Marincola, L Rivoltini, M L Salgaller, et al.Cancer Research|October 15, 1996
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptidesM L Salgaller, F M Marincola, J N Cormier, et al.CA: a Cancer Journal for Clinicians|February 24, 2001
Dendritic cell-based immunotherapy for prostate cancerB A Tjoa, P A Lodge, M L Salgaller, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1993
Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapiesP H Hand, P F Robbins, M L Salgaller, et al.Pageof 5